Design and stability of pediatric oral formulation of imatinib.

Hinterlang, Mélanie; Gendron, Amandine; Fleury, Thomas; Rieutord, André; Vrana, Anastasia; Schlatter, Joël; Annereau, Maxime

Hinterlang, Mélanie; Gendron, Amandine; Fleury, Thomas; Rieutord, André; Vrana, Anastasia; Schlatter, Joël; Annereau, Maxime.

Afiliação

Hinterlang M; Pharmacie, Hôpital Universitaire Necker - Enfants Malades, Paris, France.
Gendron A; Pharmacie, Institut Gustave Roussy, Villejuif, France.
Fleury T; Pharmacie, Institut Gustave Roussy, Villejuif, France.
Rieutord A; Pharmacie, Institut Gustave Roussy, Villejuif, France.
Vrana A; Pharmacie, Institut Gustave Roussy, Villejuif, France.
Schlatter J; Pharmacie, Hôpital Universitaire Necker - Enfants Malades, Paris, France.
Annereau M; Département Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé, Paris, France.

J Oncol Pharm Pract ; 28(2): 337-342, 2022 Mar.

Article em En | MEDLINE | ID: mdl-33522386

Assuntos

Pediatria; Administração Oral; Criança; Estabilidade de Medicamentos; Humanos; Mesilato de Imatinib; Suspensões; Comprimidos

Palavras-chave

Imatinib; chronic myeloid leukemia; oral suspension; pediatric formulation; stability

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pediatria Limite: Child / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google